Neuroendocrine Carcinoma Treatment Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-01-08　·　153 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 2.35 Bn
2033 年預估規模: USD 4.08 Bn
年複合成長率 CAGR: 8.2%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-01-08頁數 153報告編號 CMI9188

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Neuroendocrine Carcinoma Treatment Market , By Drug Class (Somatostatin Analogs, Chemotherapeutic Agents, Targeted Therapy Drugs, Immunomodulatory Drugs, Peptide Receptor Radionuclide Therapy (PRRT), and Hormonal Agents), By Indication Type (Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Pulmonary Neuroendocrine Tumors, Thyroid Neuroendocrine Tumors, and Others (e.g. Adrenal Gland Neuroendocrine Tumors)), By End User (Hospitals, Cancer Treatment Centers, Ambulatory Surgery Centers, Home Care, and Research Institutes), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East and Africa)

報告摘要

According to Coherent Market Insights, the global neuroendocrine carcinoma treatment market is estimated to be valued at USD 2.35 Bn in 2026 and is expected to reach USD 4.08 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033. The global neuroendocrine carcinoma treatment market represents a critical segment within the oncology therapeutics landscape, addressing the complex clinical needs of patients diagnosed with neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These rare but increasingly recognized malignancies arise from neuroendocrine cells distributed throughout various organ systems, including the gastrointestinal tract, pancreas, lungs, and other anatomical sites. Neuroendocrine carcinomas are characterized by their heterogeneous nature, varying degrees of differentiation, and diverse clinical presentations, necessitating sophisticated treatment approaches that combine surgical interventions, systemic therapies, and targeted molecular treatments. The market encompasses a comprehensive range of therapeutic modalities including somatostatin analogs, targeted therapy agents, chemotherapy regimens, peptide receptor radionuclide therapy (PRRT), and emerging immunotherapeutic approaches. With advancing diagnostic capabilities, improved understanding of tumor biology, and growing awareness among healthcare professionals, the identification and treatment of neuroendocrine carcinomas have significantly evolved. The increasing incidence rates, coupled with enhanced survival outcomes through innovative treatment strategies, drives substantial market growth opportunities. This specialized therapeutic market continues to attract significant pharmaceutical investment, fostering the development of novel treatment paradigms and personalized medicine approaches tailored to specific tumor characteristics and patient profiles. Market Dynamic The global neuroendocrine carcinoma treatment market is propelled by several robust drivers, including the rising incidence of neuroendocrine tumors worldwide, attributed to improved diagnostic techniques and increased clinical awareness among healthcare professionals. Advanced imaging technologies, molecular diagnostics, and biomarker identification have significantly enhanced early detection capabilities, leading to expanded patient populations requiring therapeutic intervention. The growing investment in research and development by pharmaceutical companies has accelerated the introduction of innovative treatment modalities, including targeted therapies, immunotherapies, and precision medicine approaches that offer improved efficacy and reduced adverse effects compared to conventional chemotherapy regimens. However, the market faces considerable restraints, primarily stemming from the rare nature of neuroendocrine carcinomas, which limits patient populations for clinical trials and creates challenges in achieving regulatory approvals for new treatments. High treatment costs, particularly for novel targeted therapies and peptide receptor radionuclide therapy, create significant financial burdens for healthcare systems and patients, potentially limiting market accessibility. Additionally, the heterogeneous nature of neuroendocrine tumors complicates treatment standardization, while limited awareness among primary care physicians may result in delayed diagnoses and suboptimal treatment outcomes. Despite these challenges, substantial opportunities emerge from the expanding pipeline of investigational drugs, increasing adoption of combination therapy approaches, and growing focus on personalized treatment strategies based on tumor genetics and patient-specific factors. The rising prevalence in developing economies, coupled with improving healthcare infrastructure and increasing healthcare expenditure, presents significant market expansion opportunities for pharmaceutical companies seeking to address unmet medical needs in neuroendocrine carcinoma treatment. Key Features of the Study • This report provides in-depth analysis of the global neuroendocrine carcinoma treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global neuroendocrine carcinoma treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Novartis AG, Ipsen Pharma, Pfizer Inc, Bristol Myers Squibb, Eli Lilly and Company, Merck & Co, Amgen, Boehringer Ingelheim, Teva Pharmaceutical Industries, Hutchison China MediTech, Exelixis Inc, Chiasma Inc, Advanced Accelerator Applications (Novartis Radioligand), Progenics Pharmaceuticals, and AbbVie Inc. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global neuroendocrine carcinoma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuroendocrine carcinoma treatment market Market Segmentation • Drug Class Insights (Revenue, USD Bn, 2021 - 2033) o Somatostatin Analogs o Chemotherapeutic Agents o Targeted Therapy Drugs o Immunomodulatory Drugs o Peptide Receptor Radionuclide Therapy (PRRT) o Hormonal Agents • Indication Type Insights (Revenue, USD Bn, 2021 - 2033) o Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) o Pulmonary Neuroendocrine Tumors o Thyroid Neuroendocrine Tumors o Others (e.g. Adrenal Gland Neuroendocrine Tumors) • End User Insights (Revenue, USD Bn, 2021 - 2033) o Hospitals o Cancer Treatment Centers o Ambulatory Surgery Centers o Home Care o Research Institutes • Route of Administration Insights (Revenue, USD Bn, 2021 - 2033) o Oral o Parenteral • Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Regional Insights (Revenue, USD Bn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Novartis AG o Ipsen Pharma o Pfizer Inc o Bristol Myers Squibb o Eli Lilly and Company o Merck & Co o Amgen o Boehringer Ingelheim o Teva Pharmaceutical Industries o Hutchison China MediTech o Exelixis Inc o Chiasma Inc o Advanced Accelerator Applications (Novartis Radioligand) o Progenics Pharmaceuticals o AbbVie Inc

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Neuroendocrine Carcinoma Treatment Market, By Drug Class  Global Neuroendocrine Carcinoma Treatment Market, By Indication Type  Global Neuroendocrine Carcinoma Treatment Market, By End User  Global Neuroendocrine Carcinoma Treatment Market, By Route of Administration  Global Neuroendocrine Carcinoma Treatment Market, By Distribution Channel  Global Neuroendocrine Carcinoma Treatment Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Driver o Restraint o Opportunity o Impact Analysis o Key Developments o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Merger and Acquisition Scenario o Industry Trends 4. Global Neuroendocrine Carcinoma Treatment Market, By Drug Class, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Somatostatin Analogs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Chemotherapeutic Agents  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Targeted Therapy Drugs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Immunomodulatory Drugs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Peptide Receptor Radionuclide Therapy (PRRT)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Hormonal Agents  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 5. Global Neuroendocrine Carcinoma Treatment Market, By Indication Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Pulmonary Neuroendocrine Tumors  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Thyroid Neuroendocrine Tumors  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others (e.g. Adrenal Gland Neuroendocrine Tumors)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 6. Global Neuroendocrine Carcinoma Treatment Market, By End User, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospitals  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Cancer Treatment Centers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Ambulatory Surgery Centers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Home Care  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Research Institutes  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 7. Global Neuroendocrine Carcinoma Treatment Market, By Route of Administration, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Oral  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Parenteral  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 8. Global Neuroendocrine Carcinoma Treatment Market, By Distribution Channel, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 9. Global Neuroendocrine Carcinoma Treatment Market, By Region, 2021 - 2033, Value (USD Bn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Indication Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn) o South Africa o North Africa o Central Africa 10. Competitive Landscape o Novartis AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Ipsen Pharma  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Pfizer Inc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o BristolMyers Squibb  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Eli Lilly and Company  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Merck & Co  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Amgen  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Boehringer Ingelheim  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Teva Pharmaceutical Industries  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Hutchison China MediTech  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Exelixis Inc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Chiasma Inc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Advanced Accelerator Applications (Novartis Radioligand)  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Progenics Pharmaceuticals  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AbbVie Inc  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 11. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 12. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on ‘Neuroendocrine Carcinoma Treatment Market' - Global forecast to 2033

提及公司

Novartis AGIpsen PharmaPfizer IncBristol Myers SquibbEli Lilly and CompanyMerck & CoAmgenBoehringer IngelheimTeva Pharmaceutical IndustriesHutchison China MediTechExelixis IncChiasma IncAdvanced Accelerator Applications (Novartis Radioligand)Progenics PharmaceuticalsAbbVie Inc

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們